Teligent Inc Revenue Growth Rates (TLGT), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Teligent Inc   (NASDAQ: TLGT)
 

TLGT's Revenue Growth by Quarter and Year

Teligent Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

TLGT Revenue (in millions $) FY 2021 FY 2020 FY 2019 FY 2018
4th Quarter December -
3rd Quarter September -
2nd Quarter June 10.43
1st Quarter March 11.59
FY 22.02

TLGTs Annual Revenue
Teligent Inc 's Revenue in the fiscal year 2020 $ 45.31 millions
Teligent Inc 's Revenue in the fiscal year 2019 $ 65.71 millions
Teligent Inc 's Revenue in the fiscal year 2018 $ 60.32 millions
Teligent Inc 's Revenue in the fiscal year 2017 $ 67.25 millions
Teligent Inc 's Revenue in the fiscal year 2016 $ 66.88 millions




TLGT Revenue second quarter 2021 Y/Y Growth Comment
Teligent Inc reported decline in Revenue in the second quarter 2021 by -23.23% to $ 10.43 millions, from the same quarter in 2020.
The contraction in the second quarter 2021 Teligent Inc 's Revenue compares unfavorably to the Company's average Revenue rise of 29.47%.

Looking into second quarter 2021 results within Major Pharmaceutical Preparations industry 210 other companies have achieved higher Revenue growth. While Teligent Inc ' s Revenue fall of -23.23% ranks overall at the positon no. 3990 in the second quarter 2021.


TLGT Revenue ( Y/Y Growth %) 2021
 2020 2019 2018
4th Quarter December - -37.76 % 42.21 % -30.25 %
3rd Quarter September - -22.36 % -53.95 % 253.7 %
2nd Quarter June -23.23 % -25.9 % -61.9 % 193 %
1st Quarter March 55.57 % -42.43 % -64.6 % 83.76 %
FY   - -31.04 % -51.69 % -

Financial Statements
Teligent Inc 's second quarter 2021 Revenue $ 10.43 millions TLGT's Income Statement
Teligent Inc 's second quarter 2020 Revenue $ 13.59 millions Quarterly TLGT's Income Statement


TLGT Revenue (Quarter on Quarter Growth %)

 2021
 2020 2019 2018
4th Quarter December - -30.68 % -13.54 % -72 %
3rd Quarter September - 5.52 % 0.71 % -16.68 %
2nd Quarter June -9.98 % 82.42 % 41.73 % 31.71 %
1st Quarter March 16.6 % -53.35 % 15.23 % 127.02 %
FY (Year on Year)   - -31.04 % -51.69 % -


Back to TLGT Growth rate Comparisons >> Back to TLGT Growth rate Comparisons >>


Revenue second quarter 2021 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #211
Healthcare Sector #582
Overall #3990

Revenue Y/Y Growth Statistics
High Average Low
191.42 % 29.47 % -42.44 %
(Dec 31 2013)   (Mar 31 2020)
Revenue second quarter 2021 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #211
Healthcare Sector #582
Overall #3990
Revenue Y/Y Growth Statistics
High Average Low
191.42 % 29.47 % -42.44 %
(Dec 31 2013)   (Mar 31 2020)

Revenue by Quarter for the Fiscal Years 2018, 2019, 2020, 2021

Teligent Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
126.99 % 10.95 % -72.01 %
(Mar 31 2018)  


TLGT's II. Quarter Q/Q Revenue Comment
In the II. Quarter 2021 Teligent Inc disclosed drop in Revenue from the first quarter by -9.98% to $ 10.43 millions, from $ 11.59 millions achived in the previous reporting period.

Although periodic circumstance commonly energize II. Quarter 2021 Revenue, this plainly could not be substantial to rescue 's company achievement, Most analysts pointed out.

Within Major Pharmaceutical Preparations industry 243 other companies have achieved higher Revenue quarter on quarter growth. While Teligent Inc 's Revenue growth quarter on quarter, overall rank is 4101.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #244
Healthcare Sector #636
Overall #4101
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #244
Healthcare Sector #636
Overall #4101
Revenue Q/Q Growth Statistics
High Average Low
126.99 % 10.95 % -72.01 %
(Mar 31 2018)  


TLGT's II. Quarter Q/Q Revenue Comment
In the II. Quarter 2021 Teligent Inc disclosed drop in Revenue from the first quarter by -9.98% to $ 10.43 millions, from $ 11.59 millions achived in the previous reporting period.

Although periodic circumstance commonly energize II. Quarter 2021 Revenue, this plainly could not be substantial to rescue 's company achievement, Most analysts pointed out.

Within Major Pharmaceutical Preparations industry 243 other companies have achieved higher Revenue quarter on quarter growth. While Teligent Inc 's Revenue growth quarter on quarter, overall rank is 4101.


Teligent Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2021)		 12 Months Ending
(Mar 31 2021)		 12 Months Ending
(Dec 31 2020)		 12 Months Ending
(Sep 30 2020)		 12 Months Ending
(Jun 30 2020)
Cumulative Revenue 12 Months Ending $ 46.30 $ 49.45 $ 45.31 $ 51.34 $ 55.47
Y / Y Revenue Growth (TTM) -16.53 % -17.89 % -31.05 % -15.8 % -32.86 %
Year on Year Revenue Growth Overall Ranking # 2977 # 2687 # 3260 # 2702 # 2472
Seqeuential Revenue Change (TTM) -6.38 % 9.14 % -11.75 % -7.44 % -7.9 %
Seq. Revenue Growth (TTM) Overall Ranking # 2953 # 731 # 3378 # 3198 # 2347


Cumulative Revenue growth Comment
Teligent Inc showed decline, but improvement compare to trailing twelve month Revenue decrease in Mar 31 2021. If the fiscal year would end in Jun 30 2021, Teligent Inc 's annual Revenue decrease would be -16.53% year on year to $46 millions.

In the Healthcare sector 412 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 2687 to 2977.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 148
Healthcare Sector # 413
Overall # 2977

Revenue TTM Y/Y Growth Statistics
High Average Low
241.86 %
 40.72 %
-31.05 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 148
Sector # 410
S&P 500 # 2953
Cumulative Revenue growth Comment
Teligent Inc showed decline, but improvement compare to trailing twelve month Revenue decrease in Mar 31 2021. If the fiscal year would end in Jun 30 2021, Teligent Inc 's annual Revenue drop would be -16.53% year on year to $46 millions.

In the Healthcare sector 412 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 2687 to 2977.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 148
Healthcare Sector # 413
Overall # 2977

Revenue TTM Y/Y Growth Statistics
High Average Low
241.86 %
40.72 %
-31.05 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 148
Sector # 410
S&P 500 # 2953




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
TLGT's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue drop for the quarter ending Jun 30 2021 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2021
Heron Therapeutics Inc -0.99%$ -0.993 millions
Vaso Corporation-1.28%$ -1.279 millions
Thermogenesis Holdings Inc -1.83%$ -1.829 millions
Cytomx Therapeutics Inc -1.93%$ -1.927 millions
Miromatrix Medical inc -2.78%$ -2.777 millions
Diversicare Healthcare Services Inc -2.90%$ -2.896 millions
Curis Inc -3.14%$ -3.136 millions
Sunlink Health Systems Inc -3.31%$ -3.312 millions
Arvinas Inc -3.54%$ -3.536 millions
Navidea Biopharmaceuticals Inc -3.71%$ -3.709 millions
Emergent Biosolutions Inc -4.38%$ -4.383 millions
Neurocrine Biosciences Inc -4.46%$ -4.464 millions
Infusystem Holdings Inc-4.48%$ -4.481 millions
Rockwell Medical inc -4.77%$ -4.775 millions
Cv Sciences Inc -4.97%$ -4.967 millions
Acorda Therapeutics Inc -5.45%$ -5.452 millions
Cumberland Pharmaceuticals Inc -5.65%$ -5.654 millions
American Cryostem Corporation-6.24%$ -6.238 millions
Elite Pharmaceuticals Inc -6.39%$ -6.393 millions
Hill rom Holdings Inc -6.49%$ -6.489 millions
Pediatrix Medical Group Inc -7.12%$ -7.118 millions
Clovis Oncology inc -7.69%$ -7.689 millions
Lifevantage Corp-7.73%$ -7.733 millions
Wave Life Sciences Ltd -8.29%$ -8.292 millions
Pacific Health Care Organization Inc-8.39%$ -8.391 millions
Kaya Holdings Inc -9.35%$ -9.347 millions
Alerislife Inc -9.76%$ -9.757 millions
Inovio Pharmaceuticals Inc -10.01%$ -10.014 millions
U s Stem Cell Inc -10.62%$ -10.622 millions
Aclaris Therapeutics Inc -10.85%$ -10.850 millions


About Teligent Inc Revenue Growth Rates (TLGT), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: the company’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.